Incyte

About: Incyte is a company organization based out in Wilmington, Delaware, United States. It is known for research contribution in the topics: Expression vector & Ruxolitinib. The organization has 1262 authors who have published 1875 publications receiving 75015 citations. The organization is also known as: Incyte Corporation & Incyte Inc..

Method for isolating and characterizing nucleic acid sequences

Abstract: The present invention provides methods for determining nucleic acid sequences based on known sequences adjacent to the unknown sequences, and reagents for using such methods.

Down syndrome critical region 1-like 1 proteins

Abstract: The invention provides a nucleic acid molecule and fragments thereof. It also provides for the use of the nucleic acid molecule for the characterization, diagnosis, evaluation, and treatment of conditions, diseases and disorders associated with gene expression and for the production of a model system. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the nucleic acid molecule.

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study

Abstract: Background Approximately 50% of patients with polycythemia vera (PV) have PV-related symptoms at diagnosis; these symptoms might develop or worsen with time. Symptoms have been shown to negatively affect quality of life and interfere with daily activities. To our knowledge, an analysis to evaluate the relationship between blood count control and symptoms has not been published. Patients and Methods The Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices (REVEAL; NCT02252159 ) is a multicenter, noninterventional, nonrandomized prospective observational study of patients with PV in the United States. Patients included were required to have a complete blood count result within 30 days before completing the at-enrollment Myeloproliferative Neoplasm Self-Assessment Form Total Symptom Score (MPN-SAF TSS). Symptom severity was compared between those who had blood count control versus those who did not. Results At the time of enrollment, 1714 patients (94.5%) were being managed with cytoreductive therapy; 468 patients (25.8%) had complete hematologic remission (CHR), 1614 patients (89.0%) had ≥1 controlled blood count, and 1122 patients (61.9%) had ≥2 controlled blood counts. Mean MPN-SAF TSSs were similar across patients in different blood count control groups. Fatigue was the most frequently reported symptom. The severity of individual symptoms, except those of pruritus and night sweats, was not affected by CHR or the number of blood counts that were controlled. Conclusion Symptom burden in patients with PV can persist despite control of blood counts, which suggests some discordance between laboratory values and symptom burden. Consequently, regular monitoring of symptom burden should be factored into the assessment of disease control.

Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I

Abstract: Methods and pharmaceutical compositions for treatment of inflammation and arthritis using protease nexin-I as an active ingredient are disclosed.

Edg-1-receptor homolog

Abstract: The present invention provides a new edg-1 like receptor (NEDG) and polynucleotides which identify and encode NEDG. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of NEDG.